EUROASPIRE VI/ASPIRE-TO-ACTION

  • Research type

    Research Study

  • Full title

    EUROASPIRE VI/ ASPIRE TO ACTION EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION, DIABETES AND CHRONIC KIDNEY DISEASE

  • IRAS ID

    335029

  • Contact name

    Neil Poulter

  • Contact email

    n.poulter@imperial.ac.uk

  • Sponsor organisation

    European Society of Cardiology

  • Duration of Study in the UK

    5 years, 7 months, 31 days

  • Research summary

    EUROASPIRE VI/Aspire to Action is a multicentre UK study in coronary patients and individuals at high risk of developing cardiovascular disease (CVD), describing their management through lifestyle and use of drug therapies and providing an objective assessment of clinical implementation of current scientific knowledge. It is part of a larger European survey called EUROASPIRE VI. Since 1995, five EUROASPIRE surveys have been carried out by the European Society of Cardiology. The United Kingdom participated in all of these surveys except EUROASPIRE I. The UK part of EUROASPIRE V was called Aspire 3 Prevent. The results showed a wide gap between the recommendations and clinical practice with many patients not achieving the lifestyle and medical risk factors goals for CVD prevention. The Aspire to Action survey is planned for 2023-2025 to determine in hospital coronary patients and apparently healthy individuals in primary care at high risk of developing cardiovascular disease whether the European and national guidelines on cardiovascular disease prevention have been followed and if the practice of preventive cardiology in Aspire to Action has improved by comparison with those centres which took part in previous surveys. This survey will also incorporate an assessment of dysglycaemia and kidney function in all patients. The main outcome measures will be the proportions of coronary and high cardiovascular risk patients achieving the lifestyle, risk factor and therapeutic targets for cardiovascular disease prevention. The data collection will be based on a review of patient medical records and a patient interview and examination at least 6 months and at most 2 years after recruiting event. This survey
    will give a unique picture of preventive action by cardiologists and primary care physicians looking
    after patients with coronary disease and individuals at high CVD risk.

  • REC name

    London - South East Research Ethics Committee

  • REC reference

    23/PR/1515

  • Date of REC Opinion

    13 Feb 2024

  • REC opinion

    Further Information Favourable Opinion